Trial of new cancer antibody approved

Israel’s cCAM has received US FDA approval to commence trials of its CM-24 monoclonal antibody (mAb) for the treatment of various types of cancers.  CM-24 targets CEACAM1, a novel immune checkpoint protein expressed on a variety of cancer cells.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.